CAPROMORELIN TARTRATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C28H35N5O4.C4H6O6
Molecular Weight	655.6954
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O[C@H]([C@@H](O)C(O)=O)C(O)=O.CN1N=C2CCN(C[C@@]2(CC3=CC=CC=C3)C1=O)C(=O)[C@@H](COCC4=CC=CC=C4)NC(=O)C(C)(C)N

InChI

InChIKey=MJGRJCMGMFLOET-MYPSAZMDSA-N

InChI=1S/C28H35N5O4.C4H6O6/c1-27(2,29)25(35)30-22(18-37-17-21-12-8-5-9-13-21)24(34)33-15-14-23-28(19-33,26(36)32(3)31-23)16-20-10-6-4-7-11-20;5-1(3(7)8)2(6)4(9)10/h4-13,22H,14-19,29H2,1-3H3,(H,30,35);1-2,5-6H,(H,7,8)(H,9,10)/t22-,28-;1-,2-/m11/s1

HIDE SMILES / InChI

Description
Sources: http://www.aratana.com/wp-content/uploads/2016/12/ENTYCE-Pkg_Insert-8_5x11-FINAL.pdf
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/19174493 | http://adisinsight.springer.com/drugs/800011628

Capromorelin is a potent ghrelin receptor agonist. Capromorelin is indicated for appetite stimulation in dogs. Plasma insulin-like growth factor-I (IGF-I) was elevated progressively over a 5-d course of daily oral dosing in dogs. In healthy older adults at risk for functional decline, administration of the capromorelin may improve body composition and physical function. Adverse events included fatigue, insomnia, and small increases in fasting glucose, glycosylated hemoglobin, and indices of insulin resistance.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Ghrelin receptor 15 Target ID: CHEMBL4616 Sources: DOI: 10.2174/2212796807999131128125920 \| https://www.ncbi.nlm.nih.gov/pubmed/24670149	Agonist 2678		7.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Inappetence 2 Sources: http://www.aratana.com/wp-content/uploads/2016/12/ENTYCE-Pkg_Insert-8_5x11-FINAL.pdf	Palliative		Approved 8429	ENTYCE Approved Use ENTYCE is indicated for appetite stimulation in dogs Launch Date 2016
Aging 4 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19174493	Palliative		Phase II 1132	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs). Discovery of capromorelin.	2003 Feb 20	12538023
Gastric motor effects of peptide and non-peptide ghrelin agonists in mice in vivo and in vitro.	2005 Aug	15843418
Gateways to clinical trials.	2007 Apr	17520107
Growth hormone (GH)-releasing hormone and GH secretagogues in normal aging: Fountain of Youth or Pool of Tantalus?	2008	18488883
Effects of an oral growth hormone secretagogue in older adults.	2009 Apr	19174493
The prokinetic face of ghrelin.	2010	20721347
Evidence for functional ghrelin receptors on parasympathetic preganglionic neurons of micturition control pathways in the rat.	2010 Sep	20497419
Smaller cardiac cell size and reduced extra-cellular collagen might be beneficial for hearts of Ames dwarf mice.	2010 Sep 1	20827400

Patents

Sample Use Guides

In Vivo Use Guide

Dog: 3 mg/kg body weight once daily

Route of Administration: Oral

In Vitro Use Guide

In rat pituitary cell cultures, Capromorelin stimulated growth hormone release with an EC50 = 3 nM.

Name

Type

Language

CAPROMORELIN TARTRATE

Official Name

English

CP-424391-18

Code

English

2-AMINO-N-((1R)-1-(((3AR)-3A-BENZYL-2,3,3A,4,6,7-HEXAHYDRO-2-METHYL-3-OXO-5H-PYRAZOLO(4,3-C)PYRIDIN-5-YL)CARBONYL)-2-(BENZYLOXY)ETHYL)-2-METHYLPROPIONAMIDE L-(+)-TARTRATE (1:1)

Systematic Name

English

CP-424,391-18

Code

English

CAPROMORELIN TARTRATE [MI]

Common Name

English

PROPANAMIDE, 2-AMINO-N-(2-(2,3,3A,4,6,7-HEXAHYDRO-2-METHYL-3-OXO-3A-(PHENYLMETHYL)-5H-PYRAZOLO(4,3-C)PYRIDIN-5-YL)-2-OXO-1-((PHENYLMETHOXY)METHYL)ETHYL)-2-METHYL-, (R-(R*,R*))-, (R-(R*,R*))-2,3-DIHYDROXYBUTANEDIOATE (1:1)

Common Name

English

CAPROMORELIN TARTRATE [USAN]

Common Name

English

CAPIMORELIN TARTRATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C76358